Alnylam PharmaceuticalsNASDAQ: ALNY

Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial for its cardiovascular drug, Amvuttra.

Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare heart condition.

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug.  Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.

Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascular events in a study of patients with a rare heart disease.

The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events du.

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.

Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.